ProCE Banner Activity

MAGNIFY Subanalysis: Lenalidomide + Rituximab Induction Followed by Maintenance in Pts With Early Relapsed or Double-Refractory FL

Slideset Download
Conference Coverage
Rituximab plus lenalidomide showed activity, tolerable safety in patients with R/R follicular lymphoma, including those with double-refractory disease or early relapse on prior therapy.

Released: June 07, 2017

Expiration: June 06, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology